PTK2 and breast cancer: From our limited analyses on NCI-60 cells, however, only FAK-copy-gain was significantly associated with higher sensitivity to its targeted inhibitor, F14, at least in breast cancer cells; this indicates that FAK-copy-gain might be a significant molecular marker for targeted therapy with FAK inhibitors in breast cancer.